Document is current

Article History

Accepted: 22 December 2024

First Online: 24 January 2025

Declarations

:

: Open Access funding enabled and organized by CAUL and its Member Institutions. The preparation of this article was not supported by any funding source. The open access fee for this article was covered by The University of Melbourne.

: EP received speaker fees or fees from consulting or participation in Advisory Boards/Data Safety Monitoring Board from Eisai, GRIN Therapeutics, SKL Life Science, Sintetica, Sun Pharma, Takeda, and Xenon Pharma, and royalties from Wiley, Elsevier, and Wolters Kluwers, all outside the submitted work. EP is an Editorial Board member of CNS Drugs. EP was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. MT received consultancy fees from Xenon Pharmaceuticals, Angelini Pharma, Clexio Bioscience. MT is the inventor of new Kv7 activators, as described in two patents entitled “Potassium channel activators and their use in treating disorders involving hyperexcitability” (EP23220110.3), and “New modulators of Kv7 potassium channels, methods of preparation and therapeutical uses” (PCT/EP2019/052067).

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: This article is an invited review. All authors contributed to the literature search. MT drafted the initial version of sections 1 and 2, and prepared Fig. (with the help of Dr. Camilla Celentano, PhD student in Neuroscience at the University of Naples Federico II, Naples, Italy). EP prepared the initial draft of Sects. 3 and 4. Both authors participated equally in the finalization of the manuscript and met ICMJE criteria for authorship. Both authors have read and approved the final submitted manuscript, and agree to be accountable for the work.